Effectiveness of sodium-glucose

cotransporter 2 inhibitors in the treatment

of chronic heart failure

Panakhova D.Z., Maksudova P.A.

Chronic heart failure (CHF) is one of the outcomes of cardiovascular diseases (CVDs) that significantly worsens patient prognosis. For this reason, research has been ongoing

for decades to find effective drugs that can improve the prognosis for patients with CHF.

Methods. The article was prepared based on a review of literature published in peer-reviewed journals available on PubMed, eLIBRARY.RU, CyberLeninka, and other research

platforms over the last 10 years.

Results. Despite significant progress in understanding the pathogenesis and treatment of CHF, the search for effective therapies continues. One of the discoveries of recent years has been drugs from the class of sodium-glucose cotransporter 2 inhibitors (SGLT2i), the efficacy of which in CHF has been demonstrated in a number

of major clinical trials.

Conclusion. SGLT2i are antidiabetic drugs that hold an important place in the management of type 2 diabetes mellitus. They have been shown to favorably influence the course of CHF, thereby reducing cardiovascular risks and mortality from CHF.

Keywords: sodium-glucose cotransporter 2 inhibitors, chronic heart failure, diabetes mellitus, left ventricular ejection fraction, blood volume, cardiovascular diseases.

For citation: Panakhova D.Z., Maksudova P.A. Effectiveness of sodium-glucose cotransporter 2 inhibitors in chronic heart failure therapy. International Journal of Heart and Vascular Diseases. 2025. 13(48): 36-41. DOI: 10.24412/2311-1623-2025-48-47-54